Bispecific Antibody Tobemstomig Shows Promise in Neoadjuvant Melanoma Trial Despite Discontinued Development
Key Insights
The Morpheus-Melanoma (search) trial demonstrated that tobemstomig, a PD-1 (search)/LAG-3 (search) bispecific antibody, achieved an 80% pathological response rate in stage III melanoma patients, comparable to the 77.3% rate seen with nivolumab plus ipilimumab.
Tobemstomig monotherapy showed superior safety with only 2.5% of patients experiencing grade 3 or higher treatment-related adverse events, compared to 22.7% with nivolumab plus ipilimumab combination therapy.
Despite promising melanoma (search) results, further development of tobemstomig has been discontinued based on lack of clear benefit over standard anti-PD1 therapies in multiple randomized phase 2 trials across other tumor types including lung and esophageal cancers.
The randomized phase 1b/2 Morpheus-Melanoma (search) trial has revealed encouraging efficacy and safety data for tobemstomig, a novel PD-1 (search)/LAG-3 (search) bispecific antibody, in patients with resectable stage III melanoma. The study enrolled 102 patients across four treatment arms, with tobemstomig monotherapy demonstrating a pathological response rate of 80.0% compared to 77.3% for the control arm of nivolumab plus ipilimumab.
Clinical Efficacy Results
In the tobemstomig arm, 32 of 40 patients (80.0%) achieved pathological response by independent review, with 19 patients (47.5%) achieving pathological complete response and six patients (15.0%) achieving near pathological complete response, resulting in a major pathological response rate of 62.5%. The control arm of nivolumab plus ipilimumab showed 17 of 22 patients (77.3%) with pathological response, including 15 patients (68.2%) with pathological complete response and a major pathological response rate of 72.7%.
The addition of tiragolumab, an anti-TIGIT (search) antibody, to either tobemstomig or atezolizumab resulted in lower pathological response rates. The tobemstomig plus tiragolumab arm achieved a 60.0% pathological response rate, while the atezolizumab plus tiragolumab arm showed a 45.0% response rate.
Safety Profile Advantages
Tobemstomig demonstrated a notably improved safety profile compared to the nivolumab plus ipilimumab combination. Only one patient (2.5%) in the tobemstomig arm experienced grade 3 or higher treatment-related adverse events, compared to five patients (22.7%) in the nivolumab plus ipilimumab arm. The most common treatment-related adverse events with tobemstomig were fatigue (30.0%), hyperthyroidism (17.5%), and rash (17.5%).
"Although tobemstomig is administered as a single agent, it targets dual immune checkpoint blockade, effectively mimicking the benefits of a combination therapy," the researchers noted. The addition of tiragolumab increased toxicity, with three patients (15.0%) in the tobemstomig plus tiragolumab arm experiencing grade 3 or higher treatment-related adverse events.
Biomarker Insights
Comprehensive biomarker analyses revealed that baseline tumor microenvironment features were associated with pathological response across all treatment arms. Patients with higher baseline CD8+ T cell density, LAG-3 (search) protein expression, and immune-related gene signatures including IFN-γ pathway and MHC pathway showed greater likelihood of response.
Circulating tumor DNA (ctDNA) analysis provided additional insights, with 68% of pathological responders achieving ctDNA clearance by week 7 pre-surgery compared to 25% of non-responders. Among patients with pathological complete response, 50.0% achieved ctDNA clearance after one treatment cycle, increasing to 77.3% after two cycles.
Treatment Mechanism and Immune Dynamics
The study validated tobemstomig's proposed mechanism of action through detailed immune profiling. Treatment led to upregulation of immune-related gene signatures and increased CD8+ tumor-infiltrating lymphocyte density. Notably, tobemstomig tended to increase the ratio of CD8 to FOXP3 cells in the tumor microenvironment, whereas this increase was not apparent with nivolumab plus ipilimumab treatment, suggesting mechanistic differentiation between the approaches.
Development Discontinuation Despite Promise
Despite the encouraging results in melanoma (search), further development of tobemstomig has been discontinued based on results from multiple randomized phase 2 trials across several tumor types. In trials evaluating non-small cell lung cancer (search), esophageal squamous cell carcinoma (search), and renal cell carcinoma (search), tobemstomig monotherapy or combination regimens did not show clear benefit over standard-of-care regimens containing anti-PD1 therapies.
The researchers noted that "tobemstomig was unlikely to provide sufficient added benefit to support a broad development strategy as a new checkpoint inhibitor across solid tumors." However, they emphasized that "the efficacy and safety profile observed suggest that development of dual PD-1 (search)/LAG-3 (search) targeting strategies may still be warranted in selected indications, particularly melanoma (search), where LAG-3 biology may be uniquely relevant."
Clinical Implications
The trial confirms the feasibility of bispecific immune checkpoint inhibitors in early-stage disease and provides valuable comparative data for neoadjuvant immunotherapy approaches in melanoma (search). The identification of robust baseline and on-treatment biomarkers, including immune gene signatures, tumor-infiltrating lymphocyte density, and ctDNA clearance, offers potential pathways for patient enrichment and treatment stratification.
The study enrolled patients between February 2022 and August 2023, with median follow-up ranging from 11.2 to 15.2 months across treatment arms. The trial was conducted at 14 centers across Australia, France, Italy, Spain, and the United States, with 94 of 102 enrolled patients (92.2%) completing the treatment period.
These findings contribute to the growing comparative landscape of neoadjuvant immunotherapy in melanoma (search) and may help prioritize future dual checkpoint inhibitor strategies, particularly in understanding why dual PD-1 (search)/LAG-3 (search) blockade appears more effective in melanoma compared to other tumor types.